Lenz & Staehelin with Samsung Bioepis on patent nullity action
Lenz & Staehelin represented Samsung Bioepis – part of the Samsung Bioepis group, the developer of the biosimilar Pyzchiva – in a patent nullity proceedings before the Swiss Federal Patent Court.
On 12 August 2025, the Court upheld a nullity action brought by Samsung Bioepis against Janssen Biotech – a Johnson & Johnson subsidiary.
The Lenz & Staehelin team
Partner Thierry Calame (pictured) and counsel Barbara Abegg (both IP) formed the Lenz & Staehelin lineup on the matter, working together with Christoph Fraefel of SBMP, Scott Parker and Fergus Brown from Simmons & Simmons and Sebastien Versaevel.